Unknown

Dataset Information

0

Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients.


ABSTRACT: Bortezomib induced peripheral neuropathy is a dose-limiting side effect and a major concern in the treatment of multiple myeloma. To identify genetic risk factors associated with the development of this side effect in bortezomib treated multiple myeloma patients, a pharmacogenetic association study was performed using a discovery set (IFM 2005-01; n = 238) and a validation set (HOVON65/GMMG-HD4 and a Czech dataset; n = 231). After multiplicity correction, none of the 2,149 single nucleotide polymorphisms tested revealed any significant association with bortezomib induced peripheral neuropathy. However, 56 single nucleotide polymorphisms demonstrated an association with bortezomib induced peripheral neuropathy with pointwise, uncorrected significance. Pathway analysis of these polymorphisms demonstrated involvement of neurological disease (FDR <20%). Also a clear enrichment of major bortezomib metabolizing genes was found. Univariate evaluation of these 56 polymorphisms in the validation set demonstrated one single nucleotide polymorphism with pointwise significance: rs619824 in CYP17A1. (IFM 2005-01 clinicaltrials.gov identifier: NCT00200681; HOVON-65/GMMG-HD4 isrctn.org identifier: ISRCTN64455289).

SUBMITTER: Corthals SL 

PROVIDER: S-EPMC3208695 | biostudies-literature | 2011 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients.

Corthals Sophie L SL   Kuiper Rowan R   Johnson David C DC   Sonneveld Pieter P   Hajek Roman R   van der Holt Bronno B   Magrangeas Florence F   Goldschmidt Hartmut H   Morgan Gareth J GJ   Avet-Loiseau Hervé H  

Haematologica 20110726 11


Bortezomib induced peripheral neuropathy is a dose-limiting side effect and a major concern in the treatment of multiple myeloma. To identify genetic risk factors associated with the development of this side effect in bortezomib treated multiple myeloma patients, a pharmacogenetic association study was performed using a discovery set (IFM 2005-01; n = 238) and a validation set (HOVON65/GMMG-HD4 and a Czech dataset; n = 231). After multiplicity correction, none of the 2,149 single nucleotide poly  ...[more]

Similar Datasets

| S-EPMC4038108 | biostudies-literature
| S-EPMC3816208 | biostudies-literature
| S-EPMC4562796 | biostudies-literature
| S-EPMC7830235 | biostudies-literature
| S-EPMC5010494 | biostudies-literature
| S-EPMC2717758 | biostudies-literature
2016-11-23 | GSE65777 | GEO
2018-04-30 | GSE80278 | GEO
| S-EPMC6247555 | biostudies-literature
| S-EPMC7848563 | biostudies-literature